[Moderna Drops 16%, Yesterday Closed Up Over 170%] BlockBeats news, on August 20, according to BIT (bit.com) market data, Moderna (MRNA.O) dropped 16%, after closing up over 170% yesterday. Previously reported, Moderna, in collaboration with Merck, achieved significant success in the Phase III clinical trial of a personalized mRNA cancer vaccine targeting high-risk melanoma. This is the world's first mRNA cancer therapy proven effective in a large-scale Phase III trial. Following the announcement, Moderna's stock price surged nearly 177% in a single day.